OmniAb Investor Conference Presentation Deck
Sugemalimab
THE SECOND APPROVED OMNIRAT-DERIVED ANTIBODY
●
●
●
●
1351
基石药业
CSTONE
PHARMACEUTICALS
Fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) mAb, which may reduce risk of
immunogenicity and toxicity, a unique advantage over similar drugs
-
Pfizer EQR
Sugemalimab (Cejemly®) was approved in China in June of 2022 for unresectable stage III
non-small cell lung cancer (NSCLC) following concurrent or sequential chemoradiotherapy
Previously approved in China in December 2021, and launched in January 2022, for first-line
treatment of metastatic non-squamous NSCLC in combination with chemotherapy
Becomes first anti-PD-1/PD-L1 mAb approved for stage III NSCLC, and is also the only one approved
for both stage III and stage IV NSCLC
Pfizer responsible for commercializing in China via 2020 strategic collaboration with CStone
EQRx licensed exclusive rights to sugemalimab for development / commercialization outside of
China, targeting first regulatory filings ex-US in 2H 2022
42
OmniAbView entire presentation